Wednesday, January 16, 2013

NanoViricides moves ahead with anti-flu drug program shown to be superior to Tamiflu

[NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.]

January 17, 2013

NanoViricides (OTCBB:NNVC) provided Tuesday an update to its flu program, and said that both its oral anti-flu and related injectable drug have now shown "significantly superior" results to Tamiflu against an H1N1 strain of the flu that is the same type as the 2009 epidemic virus.

The previously reported animal study results were reiterated as the company also announced that a "highly optimized" floor plan for its cGMP production facility for its nanoviricide drugs has now been completed by its design team. The company’s cGMP (current good manufacturing practice) facility is being designed to produce sufficient quantities of the drugs needed for human clinical trials that will test various nanoviricide drug candidates as they advance into the FDA process further.


No comments: